Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Change in Receivables (2016 - 2025)

Pediatrix Medical (MD) has disclosed Change in Receivables for 17 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 84.91% to -$1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$30.6 million, a 196.91% decrease, with the full-year FY2025 number at -$30.6 million, down 196.91% from a year prior.
  • Change in Receivables was -$1.5 million for Q4 2025 at Pediatrix Medical, up from -$7.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $30.7 million in Q4 2021 to a low of -$21.3 million in Q1 2023.
  • A 5-year average of $557400.0 and a median of -$2.7 million in 2024 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 6012.18% in 2021, then tumbled 401.59% in 2025.
  • Pediatrix Medical's Change in Receivables stood at $30.7 million in 2021, then tumbled by 83.58% to $5.0 million in 2022, then crashed by 182.92% to -$4.2 million in 2023, then plummeted by 130.97% to -$9.7 million in 2024, then soared by 84.91% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Change in Receivables are -$1.5 million (Q4 2025), -$7.9 million (Q3 2025), and -$3.8 million (Q2 2025).